Fundraising Fox
Pelagospharma
8 employees on LinkedIn · 1 known investors
Find your way into Pelagospharma
Sign up to see every warm intro you have to Pelagospharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Pelagospharma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Pelagos Pharma develops drugs targeting hard-to-treat receptors for age-related diseases, with a focus on extending healthspan and longevity.
Investors · 1
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2022 | $540.4K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Pelagospharma do?
- Pelagos Pharma develops drugs targeting hard-to-treat receptors for age-related diseases, with a focus on extending healthspan and longevity.
- Who are Pelagospharma's investors?
- Pelagospharma's investors include Portal Innovations.